# Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy

> **NCT00904280** · PHASE3 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 239 (actual)

## Conditions studied

- Cancers, Pain
- Lower Back Pain

## Interventions

- **DRUG:** Oxymorphone ER

## Key facts

- **NCT ID:** NCT00904280
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-03
- **Primary completion:** 2003-07
- **Final completion:** 2003-07
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2009-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00904280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00904280, "Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00904280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*